Serum bile acid analysis was used to monitor the bile acid composition of bile in 16 healthy male volunteers before and during the oral administration of different doses of the gallstonedissolving bile acid, chenodeoxycholic acid. Daily chenodeoxycholic acid ingestion increased the percentage of this bile acid in bile to a new steady-state level after two to three weeks. Doses of 125, 250, 500, and 750 mg/day significantly increased the proportion of chenodeoxycholic acid in bile from 41 %to 55, 61, 78, and 79 %, respectively, during the fourth week of ingestion. The results indicate that useful information concerning chenodeoxycholic acid-induced changes in the bile acid composition of bile can be obtained solely by serum bile acid analysis, and bile collection by duodenal intubation can be avoided.
Dissolution of gallstones by oral administration of the bile acids chenodeoxycholic acid (CDCA) or ursodeoxycholic acid (UDCA) can be accomplished in selected patients. 1 -3 It is clear that these bile acids act by entering the enterohepatic circulation and producing bile that is unsaturated with respect to cholesterol, but the detailed mechanism of action is still uncertain." Studies on the effect of CDCA on the composition of the bile-acid pool and biliary lipid composition have relied on the analysis of bile samples collected by duodenal intubation.v? However, this invasive procedure is not well tolerated by most patients. We have described recently a method which enables serum to be used instead of bile to monitor the bile acid composition of the biliary bile acid pool." Using this method, we have now performed a dose-response study in which randomised doses of CDCA of 125 or 250 mg, and 500 or 750 mg, were given to male volunteers for a period of four weeks. In this study, information has been obtained solely by serum bile acid analysis on the relationship between CDCA dose and biliary bile acid composition, and also on the speed of change in the proportion of CDCA in bile during and after CDCA administration.
gallstone disease gave informed consent for the study which required their participation for 13 weeks. During this period, a total of 26 fasting blood samples (l0 ml twice per week) were collected from each volunteer at 3-or 4-day intervals. In addition, duodenal bile samples were collected as previously described" (but omitting the x-ray to check the position of the tube for ethical reasons) at the same time as blood samples in the first, fifth, and thirteenth weeks of the study. Bile collection was unsuccessful on one occasion in two subjects. The average bile acid concentration of the 46 bile samples that were collected was 27 ± 18 mmol/l (mean ± SD).
After the first week of the study, subjects ingested a low dose of CDCA of 125 or 250 rng per day for four weeks with their evening meal. Then, after four weeks without ingesting CDCA, each subject was randomly allocated a higher dose of CDCA (500 or 750 mg per day) for a further four weeks to complete the study. Ethical considerations of the study were approved by our Committee for Clinical Investigation, which required liver function tests to be performed at two-week intervals during the periods of CDCA ingestion. excellent agreement between actual and predicted mean values (Table 1) . As already noted, at high proportions of COCA in bile (> 80 %), the predictive method slightly underestimated the actual value. as the mean ± SO. However, because data were often not normal1y distributed, statistical comparisons between groups were made using the non-parametric Mann-Whitney V test for unpaired data and the Wilcoxon signed-ranks test for matched pairs.
Results

ACCURACY OF THE SERUM-PREDICTIVE
METHOD
To confirm that the bile acid composition of bile, and in particular the %COCA, can be monitored via the serum, the actual %COCA in bile was compared to the predicted %COCA in bile from serum analysis.
This was possible using 46 paired bile and serum samples, collected simultaneously before COCA ingestion and during the fourth week of COCA ingestion at a low dose (125 or 250 mg per day) or higher dose (500 or 750 mg per day). As seen in Fig. 1 agreement between actual and predicted values for individual samples was variable, the average error using the serum-predictive method to estimate the % COCA in bile being 7 ± 5 % (mean ± SO).
This error value is similar to that found in a previous study with gallstone patients.f The magnitude of the error was not significantly different between groups taking different doses of COCA, although at higher doses the predicted value was usually less than the actual value. The data in Fig. 1 were also examined as a plot of the actual versus predicted percent COCA in bile, and the correlation coefficient was 0·91 (p<O·ool). Although individual biliary COCA estimations from serum bile acid analysis were not always in good agreement with actual values, when the mean % COCA in bile was calculated for each group treated with different doses of COCA, there was The profile of biliary bile acids was predicted from serum bile acid analysis, using the regression equations established for gal1stone patients." These equations were y = 0·82x -0·4 (OCA),
where x represents the mole % of each bile acid in serum, and y represents the mole % in bile. It has been shown previously that these equations are equally applicable to subjects without gallstones, since no significant differences exist between subjects with or without gallstones with respect to the ratios of the relative concentrations of the major bile acids in fasting serum and bile."
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Each figure is the mean weekly value (± SD) for eight subjects.°p <O·02 compared to before CDCA tp <0·01 compared to before CDCA The total serum bile acid concentration in serum samples was calculated by summation of the concentrations of the four individual bile acids (DCA, CDCA, UDCA, and CA), and the average values before and during CDCA administration are volunteer by collecting serum samples twice per week. To reduce errors associated with the analysis of individual samples, the average predicted percent CDCA in bile was calculated each week for each subject, and the average weekly values (± SD) for each group taking different doses of CDCA are shown in Table 2 . A significant rise in the biliary CDCA percentage (p<0·02) was observed during the first two weeks ofCDCA ingestion, the magnitude of which was related to the daily dose of CDCA. After two weeks, there was little further increase in the % CDCA in bile, and the level remained steady during the third and fourth weeks. Doses of 500 and 750 mg per day produced a similar predicted level of CDCA in bile of between 75 and 80 % after four weeks, while the final levels produced by 125 mg and 250 mg per day were significantly less (p<O·OI) and
were 55 % and 61 %, respectively (Fig. 2) . When dose was expressed according to the body weight of each subject, it was apparent that doses of between 6·0 and 11· 5 mg/kg per day resulted in similar proportions of CDCA in bile of between 70 and 90 % (Fig. 3) .
The speed of change in the proportion of CDCA in bile upon ceasing CDCA ingestion was examined only after doses of 125 or 250 mg per day. The average time required for the % CDCA in bile to return to pre-treatment levels was 2·2 ± 0·7 weeks. We thank Mr G Watherston for help in recruiting the volunteers and collecting blood and bile samples, and Mrs H Roberts for technical assistance in 500 rng but falls to 81 % with a 750 mg dose," and diarrhoea is known to occur at higher CDCA doses, presumably due to spillover of greater than normal amounts of CDCA into the colon. From our data, there would seem to be little advantage in administering doses of CDCA larger than 500 mg/day for gallstone dissolution. At this dose, the bile of nearly all subjects studied contained greater than 70 %CDCA, and this level is known to produce bile unsaturated with cholesterol in most gallstone patients who are not obese." 6 8 However while the optimum dose of CDCA that will be effective in gallstone patients has been vigorously debated 11 12 there is general agreement that the highest success rate in dissolving gallstones is achieved at doses of 1000 mg/dayl3 or 12-15 mg/kg per day.l14 Dissolution can occur at much lower doses, such as 375 mg/day" or 3 mgjkg per dayl5, but it has not been possible to predict reliably the optimum dose for an individual patient. Monitoring of the bile lipid response to ensure that the dose of CDCA results in biliary cholesterol unsaturation has been recommended by Dowling and his colleagues,' 14 but other studies have found that the individual response to CDCA therapy cannot be predicted from biliary lipids and the cholesterol saturation index. 21316 We are currently using serum bile acid profiles to monitor doses of CDCA in individual gallstone patients so that they are taking the minimum dose that will result in the bile acid pool containing at least 70% CDCA. Long-term studies are required to see if this method of treatment will be of comparable efficacy to fixed, high-dose CDCA therapy for gallstone dissolution. Until the results of these studies are available, it is uncertain whether the determination of serum bile acid profiles will be useful to regulate CDCA dosage.
CDCA has been reported to cause transient increases in serum transaminases.P 18 Serum bile acid concentrations are a sensitive indicator of liver function. 19 2o In this study, the serum bile acid concentrations and alanine aminotransferase activities in two out of 16 subjects were raised above normal levels after doses of CDCA of 500 and 750 mg/day but not after lower doses. These results are consistent with other reports of abnormal liver function tests after CDCA treatment.f 17 18 However, these biochemical abnormalities are reversible after CDCA treatment has been stopped, and CDCA is very rarely hepatotoxic at a clinically significant level," The results of this study on the effect of different doses of CDCA on the proportion of CDCA in bile, and the speed of change in biliary CDCA during and after CDCA administration, are in general agreement with previous work. 5-7 However, all previous studies have utilised duodenal bile for bile acid analysis, while in the present study serum bile acid profiles have been used to predict the relative bile acid composition of bile. The relationship between blood and biliary bile acids has been defined previously." This predictive method is sufficiently accurate to monitor the average bile acid composition of bile for groups of subjects.
Our results confirm that the % CDCA in bile approaches a new steady-state level two to three weeks after starting COCA ingestion at doses ranging from 125 to 750 mg/day, or after ceasing CDCA ingestion at doses of 125 or 250 mg/day. The proportion of CDCA in bile is related to the dose of CDCA, whether expressed as mgjday or relative to body weight (mg/kg per day). The results also show that little further increase occurs in the relative percentage of CDCA in bile when the dose is increased from 500 to 750 rng/day or from 6·0 through to 11·5 mg/kg per day for four weeks. This is probably because the efficiency of CDCA absorption decreases at higher doses. The bioavailability or CDCA has been shown to be complete at a dose or shown in Table 3 . Doses of CDCA of 500 and 750 mg/day caused statistically significant increases in the total serum bile acid concentration, but only two subjects had raised concentrations (8 and 11 fLmol/1 during doses of 500 and 750 mg/day) which were above our normal laboratory reference range for fasting serum bile acids (1-6 fLmolJI). These two subjects were also the only volunteers in the study whose serum alanine aminotransferase levels were increased more than two-fold and were outside the normal range after four weeks administration of CDCA.
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